Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
暂无分享,去创建一个
T. Su | Han‐Chieh Lin | Mu-Hong Chen | Chia‐Fen Tsai | Yen‐Po Wang | C. Chu | Yi‐Hsiang Huang | M. Hou | F. Lee | Ching‐Liang Lu
[1] Karl Broich,et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. , 2016, JAMA neurology.
[2] P. Tandon,et al. Fecal microbiota transplantation in the management of hepatic encephalopathy , 2016, Hepatology.
[3] Tim D Spector,et al. Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.
[4] Jingyuan Fu,et al. Proton pump inhibitors affect the gut microbiome , 2015, Gut.
[5] Nora C. Toussaint,et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. , 2015, Gastroenterology.
[6] F. Jessen,et al. Risk of dementia in elderly patients with the use of proton pump inhibitors , 2015, European Archives of Psychiatry and Clinical Neuroscience.
[7] B. Kronenberger,et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis , 2015, Alimentary pharmacology & therapeutics.
[8] M. Merli,et al. The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[9] Philip Wong,et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.
[10] B. Sharma,et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] Andmorgan R. Fisher,et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. , 2014, Journal of hepatology.
[12] J. Bajaj. The role of microbiota in hepatic encephalopathy , 2014, Gut microbes.
[13] E. di Giulio,et al. Proton pump inhibitor therapy and potential long-term harm , 2014, Current opinion in endocrinology, diabetes, and obesity.
[14] J. Hughes,et al. Proton Pump Inhibitor–Associated Hypomagnesemia: What Do FDA Data Tell Us? , 2013, The Annals of pharmacotherapy.
[15] Walter Wai-Yip Chan,et al. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] Jaw-Town Lin,et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. , 2012, JAMA.
[17] K. Lapane,et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis , 2012, Alimentary pharmacology & therapeutics.
[18] Samir Samman,et al. Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies , 2012, British Journal of Nutrition.
[19] I. Boin,et al. Correlation between serum magnesium levels and hepatic encephalopathy in immediate post liver transplantation period. , 2012, Transplantation proceedings.
[20] Anil K. Jain,et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] H. Dupont,et al. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2011, Alimentary pharmacology & therapeutics.
[22] A. Zinsmeister,et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture , 2011, Alimentary pharmacology & therapeutics.
[23] Kyeong Ok Kim,et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2011, Scandinavian journal of gastroenterology.
[24] R. Butterworth. Hepatic encephalopathy: A central neuroinflammatory disorder? , 2011, Hepatology.
[25] Ching-Lan Cheng,et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan , 2011, Pharmacoepidemiology and drug safety.
[26] Y. Chawla,et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. , 2010, Journal of hepatology.
[27] Jaw-Town Lin,et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. , 2010, Gastroenterology.
[28] R. Jensen,et al. Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.
[29] R. Prakash,et al. Mechanisms, diagnosis and management of hepatic encephalopathy , 2010, Nature Reviews Gastroenterology &Hepatology.
[30] S. Hamid,et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. , 2010, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.
[31] C. Leevy,et al. Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.
[32] B. Gómez-Anson,et al. Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis , 2009, The American Journal of Gastroenterology.
[33] R. Hoffmann,et al. Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.
[34] R. Jalan,et al. Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis , 2009, Alimentary pharmacology & therapeutics.
[35] E. Björnsson,et al. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis , 2008, European journal of gastroenterology & hepatology.
[36] F. Azzaroli,et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? , 2008, World journal of gastroenterology.
[37] A. Sanyal,et al. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.
[38] A. Sanyal,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. , 2007, The American journal of gastroenterology.
[39] Ritesh Agarwal,et al. Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy , 2007, Hepatology.
[40] B. Batuwitage,et al. Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.
[41] N. Shaheen,et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial , 2005, Hepatology.
[42] C. Sakamoto,et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[43] M. Uribe,et al. Hepatic encephalopathy: a review. , 2003, Annals of hepatology.
[44] Y. Naito,et al. A new mechanism for anti‐inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil–endothelial cell interactions , 2000, Alimentary pharmacology & therapeutics.
[45] T. Ishizaki,et al. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.
[46] N. Assy,et al. Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. , 1999, Gastrointestinal endoscopy.
[47] E. Strauss,et al. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. , 1998, Hepato-gastroenterology.
[48] S. O'keefe,et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole , 1996, Alimentary pharmacology & therapeutics.
[49] M. Merli,et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt , 1996, Digestive Diseases and Sciences.
[50] S. Binkley,et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.
[51] Kaoru Kobayashi,et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.
[52] G. Marchesini,et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross‐over comparison , 1993, Journal of internal medicine.
[53] E. Strauss,et al. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. , 2003, Annals of hepatology.
[54] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.